TY - JOUR
T1 - Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure
AU - Lentine, Krista L.
AU - Rey, Lisa A.Rocca
AU - Kolli, Swathy
AU - Bacchi, Giuliana
AU - Schnitzler, Mark A.
AU - Abbott, Kevin C.
AU - Xiao, Huiling
AU - Brennan, Daniel C.
PY - 2008/7
Y1 - 2008/7
N2 - Background and objectives: This study examined the risks, predictors, and mortality implications of cerebrovascular disease events after kidney transplantation in a national cohort. Design, setting, participants, & measurements: This analysis used United States Renal Data System registry data to study retrospectively Medicare-insured kidney transplant candidates (n = 51,504), recipients (n = 29,614), and recipients with allograft failure (n = 2954) in 1995 through 2002. New-onset cerebrovascular disease events including ischemic stroke, hemorrhagic stroke, and transient ischemic attacks were ascertained from billing records, and participants were followed until Medicare-end or December 31, 2002. Multivariable survival analysis was used to compare cerebrovascular disease event incidence and risk profiles among the study samples. Results: The cumulative, 3-yr incidence of de novo cerebrovascular disease events after transplantation was 6.8% and was lower than adjusted 3-yr estimates of 11.8% on the waiting list and 11.2% after graft loss. In time-dependent regression, transplantation predicted a 34% reduction in subsequent, overall cerebrovascular disease events risk compared with remaining on the waiting list, whereas risk for cerebrovascular disease events increased >150% after graft failure. Similar relationships with transplantation and graft loss were observed for each type of cerebrovascular disease event. Smoking was a potentially preventable correlate of posttransplantation cerebrovascular disease events. Women were not protected. All forms of cerebrovascular disease event diagnoses after transplantation predicted increased mortality. Conclusions: Along with known benefits for cardiac complications, translantation with sustained graft function seems to reduce risk for vascular disease events involving the cerebral circulation.
AB - Background and objectives: This study examined the risks, predictors, and mortality implications of cerebrovascular disease events after kidney transplantation in a national cohort. Design, setting, participants, & measurements: This analysis used United States Renal Data System registry data to study retrospectively Medicare-insured kidney transplant candidates (n = 51,504), recipients (n = 29,614), and recipients with allograft failure (n = 2954) in 1995 through 2002. New-onset cerebrovascular disease events including ischemic stroke, hemorrhagic stroke, and transient ischemic attacks were ascertained from billing records, and participants were followed until Medicare-end or December 31, 2002. Multivariable survival analysis was used to compare cerebrovascular disease event incidence and risk profiles among the study samples. Results: The cumulative, 3-yr incidence of de novo cerebrovascular disease events after transplantation was 6.8% and was lower than adjusted 3-yr estimates of 11.8% on the waiting list and 11.2% after graft loss. In time-dependent regression, transplantation predicted a 34% reduction in subsequent, overall cerebrovascular disease events risk compared with remaining on the waiting list, whereas risk for cerebrovascular disease events increased >150% after graft failure. Similar relationships with transplantation and graft loss were observed for each type of cerebrovascular disease event. Smoking was a potentially preventable correlate of posttransplantation cerebrovascular disease events. Women were not protected. All forms of cerebrovascular disease event diagnoses after transplantation predicted increased mortality. Conclusions: Along with known benefits for cardiac complications, translantation with sustained graft function seems to reduce risk for vascular disease events involving the cerebral circulation.
UR - http://www.scopus.com/inward/record.url?scp=49149101549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49149101549&partnerID=8YFLogxK
U2 - 10.2215/CJN.03080707
DO - 10.2215/CJN.03080707
M3 - Article
C2 - 18385393
AN - SCOPUS:49149101549
SN - 1555-9041
VL - 3
SP - 1090
EP - 1101
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
IS - 4
ER -